Comprehensive Frailty Assessment
This trial is active, not recruiting.
|Conditions||myeloma, multiple, paraproteinemias, hematologic neoplasms|
|Sponsor||Ohio State University Comprehensive Cancer Center|
|Start date||April 2014|
|End date||June 2017|
|Trial size||111 participants|
|Trial identifier||NCT02033928, OSU-13135|
The purpose of this research study is to describe a patients' fitness before and after treatment (whether that treatment be chemotherapy or a transplant). Fitness is a way of measuring a patient's current quality of health. With surveys, questionnaires and blood tests, we hope to create a tool that will give a good picture of patients' ability to tolerate treatment. In the future, we hope to devise the best treatment for a patient based on their "fitness".
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
Change in Comprehensive Frailty Assessment
time frame: up to 14 months
Time to progression
time frame: date of enrollment to date of documented clinical progression up to two years post-enrollment
Male or female participants at least 18 years old.
Inclusion Criteria: - patients with a plasma cell dyscrasia AND/OR any patient receiving a stem cell transplant for a hematologic malignancy at The Ohio State University - at least 18 years of age Exclusion Criteria: - Any medical or psychiatric condition that would make it difficult for the patient to comply with study procedures.
|Official title||Comprehensive Frailty Assessment|
|Principal investigator||Ashley Rosko, MD|
Call for more information